Taysha Gene Therapies (TSHA) EBITDA Margin (2023 - 2025)
Taysha Gene Therapies (TSHA) reported EBITDA Margin of 2334.98% for Q4 2025, down 134923.0% on a YoY basis from N/an in Q4 2024, and down 73.34% sequentially from 1347.08% in Q2 2025.
Taysha Gene Therapies (TSHA) EBITDA Margin (2023 - 2025) Analysis & Trends
Taysha Gene Therapies (TSHA) has 3 years of EBITDA Margin data on file, last reported at 2334.98% in Q4 2025.
- For the quarter ending Q4 2025, EBITDA Margin fell 134923.0% year-over-year to 2334.98%; the trailing twelve-month figure through Mar 2026 stood at 4145.18% (down 291941.0% YoY), and the FY2025 full-year result was 2009.05%, down 91150.0% from the prior year.
- EBITDA Margin retreated to 2334.98% in Q4 2025, from 1347.08% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 342.39% in Q3 2023 to a low of 2334.98% in Q4 2025.
- A 3-year average of 1072.44% and a median of 976.37% in 2023 frame the typical range for EBITDA Margin.
- Peak annual rise in EBITDA Margin reached 56830 bps in 2025, while the deepest fall reached 134923 bps in 2025.
- Tracing TSHA's EBITDA Margin over 3 years: stood at 450.78% in 2023, then slumped by 119 bps to 985.76% in 2024, then plunged by 137 bps to 2334.98% in 2025.
- Business Quant data shows TSHA's EBITDA Margin at 2334.98% in Q4 2025, 1347.08% in Q2 2025, and 930.54% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Taysha Gene Therapies | 2.14 Bn | 2.14 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2,334.98% |
| Jun 30, 2025 | -1,347.08% |
| Mar 31, 2025 | -930.54% |
| Dec 31, 2024 | -985.76% |
| Sep 30, 2024 | -1,448.43% |
| Jun 30, 2024 | -1,915.38% |
| Mar 31, 2024 | -713.28% |
| Dec 31, 2023 | -450.78% |
| Sep 30, 2023 | -342.39% |
| Jun 30, 2023 | -976.37% |
| Mar 31, 2023 | -351.87% |